- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
>Human Cell Expressed
>Rat VEGFR2 / Flk-1 / CD309 / KDR Protein (Fc Tag)
|Catalog||Size (Price)||Quantity||In Stock||Operation|
Kinase insert domain receptor Protein Datasheet
KDR / VEGFR2 / CD309 Protein Price Inquiry ( Available Sizes )
KDR / VEGFR2 / CD309 Protein Product Information
A DNA sequence encoding the rat KDR (Q5PQU0) (Met1-Glu760) was expressed, fused with the Fc region of human IgG1 at the C-terminus.
|Expression Host:||Human Cells|
KDR / VEGFR2 / CD309 Protein QC Testing
|Purity:||> 95% as determined by SDS-PAGE||SDS-PAGE:
KDR / VEGFR2 / CD309 protein
|Immobilized mouse VEGF164 (Cat:50159-MNAB) at 10 μg/ml (100 μl/well) can bind rat KDR-Fc, The EC50 of rat KDR-Fc is 0.07-0.15 μg/ml.|
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||Ala 20|
The recombinant rat KDR/Fc is a disulfide-linked homodimer. The reduced monomer comprises 982 amino acids and has a predicted molecular mass of 110 kDa. The apparent molecular mass of the protein is approximately 120 kDa in SDS-PAGE under reducing conditions.
|Formulation:||Lyophilized from sterile PBS, pH7.4.
KDR / VEGFR2 / CD309 Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
KDR / VEGFR2 / CD309 Protein Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|VEGFR2/Flk-1/CD309||Human||VEGFR2/Flk-1/CD309/Fc Protein, Recombinant||10012-H02H|
|VEGFR2/Flk-1/CD309||Human||VEGFR2 / Flk-1 / CD309 Protein, Recombinant||10012-H08H|
|VEGFR2/Flk-1/CD309||Human||KDR / VEGFR2 / CD309 Protein, Recombinant, with GST Tag||10012-H20B1|
|VEGFR2/Flk-1/CD309||Mouse||KDR / VEGFR2 / CD309 Protein, Recombinant||50998-M02H|
|VEGFR2/Flk-1/CD309||Mouse||KDR / VEGFR2 / CD309 Protein, Recombinant||50998-M08H|
|VEGFR2/Flk-1/CD309||Rat||KDR / VEGFR2 / CD309 Protein, Recombinant||80113-R02H|
|VEGFR2/Flk-1/CD309||Rat||KDR / VEGFR2 / CD309 Protein, Recombinant||80113-R08H|
KDR / VEGFR2 / CD309 Protein Description
Vascular endothelial cell growth factor (VEGF), also known as vascular permeability factor, is an endothelial cell mitogen, which stimulates angiogenesis by binding to specific receptors (VEGFRs) on the surface of vascular endothelial cells. The VEGF ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. All the three receptors for VEGF, VEGFR1~3, belong to CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs), and contains seven Ig-like C2-type domains in the ECD, as well as a intracellular protein kinase domain. VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
- Terman BI. et al., 1992, Biochem Biophys Res Commun. 187: 1579-86.
- McTigue MA. et al., 1999, Structure. 7: 319-30.
- Patterson C. et al., 1995, J Biol Chem. 270: 23111-8.
- Holmqvist K. et al., 2004, J Biol Chem. 279: 22267-75.